Key result
IV atropine during MI may worsen ischemia and provoke serious arrhythmias, warranting restricted use.
Why the study?
Intravenously administered atropine sulfate is commonly used for bradycardias during myocardial infarction, but its safety and effects on ischemia in humans are not well documented.
Does intravenously administered atropine sulfate cause serious arrhythmias or increase ischemia in patients with myocardial infarction?
Does intravenously administered atropine sulfate cause serious arrhythmias or increase ischemia in patients with myocardial infarction?
Intravenous atropine should be used cautiously during myocardial infarction due to potential risks of serious arrhythmias and increased ischemia.
Answers are grounded in this paper and cite their sources.
May warrant selective atropine avoidance in MI; leaves open need for randomized confirmation of risks.
Intravenously administered atropine sulfate is commonly used for the control of bradycardias during myocardial infarction. There is increasing evidence that this may not be beneficial to the patient and that serious arrhythmias may be produced. Atropine has also been demonstrated to increase the area of ischemia during myocardial infarction in dogs, but this has not been well documented in humans. It is suggested that atropine be used cautiously during myocardial infarction, and only when the hemodynamic situation clearly warrants its use or when a serious cardiac arrhythmia exists. (JAMA228:1414-1416, 1974)
No takes yet. Share an insight, caveat, or question.
Richman Sm (1974) conducted a review in Myocardial infarction. Atropine sulfate was evaluated. Intravenously administered atropine during myocardial infarction may increase ischemia and produce serious arrhythmias, warranting cautious use only when hemodynamically justified.
Synapse has enriched 10 related papers. Consider them for comparative context: